Comparisons in fluctuation of muscle strength and function in patients with immune‐mediated neuropathy treated with intravenous versus subcutaneous immunoglobulin

Autor: Johannes Jakobsen, Ingelise Christiansen, Lars Høj Markvardsen

Publikováno v: Christiansen, I, Markvardsen, L & Jakobsen, J 2018, ' Comparisons in fluctuation of muscle strength and function in patients with immune mediated neuropathy treated with intravenous versus subcutaneous immunoglobulin ', Muscle & Nerve, vol. 57, no. 4, pp. 610-614 . https://doi.org/10.1002/mus.25967

INTRODUCTION: Variation of muscle strength and function have not been studied in patients with chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy whose treatment regimen has been changed from intravenous to subcutaneous

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31586e082e33148cdd383e12f6271a4d
https://doi.org/10.1002/mus.25967

Subcutaneous immunoglobulin as first-line therapy in treatment-naive patients with chronic inflammatory demyelinating polyneuropathy: randomized controlled trial study

Autor: Johannes Jakobsen, Henning Andersen, Danish Cidp, Ingelise Christiansen, Niels Kjær Olsen, Lars Høj Markvardsen, Søren H. Sindrup

Publikováno v: Markvardsen, L H, Sindrup, S H, Christiansen, I, Olsen, N K, Jakobsen, J, Andersen, H & Danish CIDP and MMN Study Group 2017, ' Subcutaneous immunoglobulin as first-line therapy in treatment-naive patients with chronic inflammatory demyelinating polyneuropathy : randomized controlled trial study ', European Journal of Neurology, vol. 24, no. 2, pp. 412-418 . https://doi.org/10.1111/ene.13218
Markvardsen, L H, Sindrup, S H, Christiansen, I, Olsen, N K, Jakobsen, J & Andersen, H 2017, ' Subcutaneous immunoglobulin as first-line therapy in treatment-naive patients with chronic inflammatory demyelinating polyneuropathy: randomized controlled trial study. ', European Journal of Neurology, vol. 24, no. 2, pp. 412-418 . https://doi.org/10.1111/ene.13218
Markvardsen, L H, Sindrup, S H, Christiansen, I, Olsen, N K, Jakobsen, J, Andersen, H & On behalf of The Danish CIDP and MMN Study Group 2017, ' Subcutaneous immunoglobulin as first-line therapy in treatment-naive patients with chronic inflammatory demyelinating polyneuropathy : randomized controlled trial study ', European Journal of Neurology, vol. 24, no. 2, pp. 412-418 . https://doi.org/10.1111/ene.13218

BACKGROUND AND PURPOSE: Subcutaneous immunoglobulin (SCIG) is effective as maintenance treatment in chronic inflammatory demyelinating polyneuropathy (CIDP). We investigated whether multiple subcutaneous infusions are as effective as conventional the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b1c9fca944122c2bb13a8e50f0295e7
https://doi.org/10.1111/ene.13218

Diffusion tensor imaging can be used to detect lesions in peripheral nerves in patients with chronic inflammatory demyelinating polyneuropathy treated with subcutaneous immunoglobulin

Autor: Steffen Ringgaard, Henning Andersen, Michael Vaeggemose, Lars Høj Markvardsen

Publikováno v: Markvardsen, L H, Vaeggemose, M, Ringgaard, S & Andersen, H 2016, ' Diffusion tensor imaging can be used to detect lesions in peripheral nerves in patients with chronic inflammatory demyelinating polyneuropathy treated with subcutaneous immunoglobulin ', Neuroradiology, vol. 58, no. 8, pp. 745-752 . https://doi.org/10.1007/s00234-016-1692-z

INTRODUCTION: Magnetic resonance imaging (MRI) with diffusion tensor imaging (DTI) has shown that fractional anisotropy (FA) is lower in peripheral nerves in chronic inflammatory demyelinating polyneuropathy (CIDP). We examined whether DTI correlates

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d00743d151faf1516b348798d5a05e30
https://doi.org/10.1007/s00234-016-1692-z

Subcutaneous immunoglobulin treatment in CIDP and MMN. Efficacy, treatment satisfaction and costs

Autor: Lars Høj Markvardsen, Thomas Harbo

Publikováno v: Markvardsen, L H & Harbo, T 2017, ' Subcutaneous immunoglobulin treatment in CIDP and MMN. Efficacy, treatment satisfaction and costs ', Journal of the Neurological Sciences, vol. 378, pp. 19-25 . https://doi.org/10.1016/j.jns.2017.04.039

Subcutaneous administration of immunoglobulin (SCIG) in chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy (MMN) has been reported in several case reports and in a few randomized trials during the last decade. In

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be6a34755c1a736af81adbe94f64b2fe
https://pure.au.dk/portal/da/publications/subcutaneous-immunoglobulin-treatment-in-cidp-and-mmn-efficacy-treatment-satisfaction-and-costs(01045eed-8e3b-46b7-8ed7-f9dd5a519afa).html

Improvement of hemoglobin levels after a switch from intravenous to subcutaneous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy

Autor: Lars Høj, Markvardsen, Ingelise, Christiansen, Johannes, Jakobsen

Publikováno v: Transfusion. 56(10)

Intravenous immunoglobulin (IVIG) is recommended treatment for chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy (MMN). Recent studies have demonstrated that subcutaneous immunoglobulin (SCIG) is feasible, safe,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::1a71a9ae235ff4fbfd3561381affc70c
https://pubmed.ncbi.nlm.nih.gov/27401495